1680 related articles for article (PubMed ID: 29455675)
1. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
Golding B; Luu A; Jones R; Viloria-Petit AM
Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Sgambato A; Casaluce F; Maione P; Gridelli C
Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
5. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors.
Spagnuolo A; Maione P; Gridelli C
Expert Opin Emerg Drugs; 2018 Sep; 23(3):231-241. PubMed ID: 30251885
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
7. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
8. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
9. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
10. ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer.
Rosas G; Ruiz R; Araujo JM; Pinto JA; Mas L
Crit Rev Oncol Hematol; 2019 Apr; 136():48-55. PubMed ID: 30878128
[TBL] [Abstract][Full Text] [Related]
11. Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.
Ai X; Niu X; Chang L; Chen R; Ou SI; Lu S
Lung Cancer; 2018 Sep; 123():83-86. PubMed ID: 30089600
[TBL] [Abstract][Full Text] [Related]
12. Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Remon J; Pignataro D; Novello S; Passiglia F
Cancer Treat Rev; 2021 Apr; 95():102178. PubMed ID: 33743408
[TBL] [Abstract][Full Text] [Related]
13. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
14. Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).
Kong X; Pan P; Sun H; Xia H; Wang X; Li Y; Hou T
J Med Chem; 2019 Dec; 62(24):10927-10954. PubMed ID: 31419130
[TBL] [Abstract][Full Text] [Related]
15. Canadian perspectives: update on inhibition of
Melosky B; Cheema P; Agulnik J; Albadine R; Bebb DG; Blais N; Burkes R; Butts C; Card PB; Chan AMY; Hirsh V; Ionescu DN; Juergens R; Morzycki W; Poonja Z; Sangha R; Tehfe M; Tsao MS; Vincent M; Xu Z; Liu G
Curr Oncol; 2018 Oct; 25(5):317-328. PubMed ID: 30464681
[TBL] [Abstract][Full Text] [Related]
16. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
Singhi EK; Horn L
Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
18. Treatment of ALK-positive nonsmall cell lung cancer: recent advances.
Thai AA; Solomon BJ
Curr Opin Oncol; 2018 Mar; 30(2):84-91. PubMed ID: 29256901
[TBL] [Abstract][Full Text] [Related]
19. Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Rocco D; Battiloro C; Della Gravara L; Gridelli C
Drug Saf; 2019 Feb; 42(2):199-209. PubMed ID: 30649741
[TBL] [Abstract][Full Text] [Related]
20. Proteasome Inhibition Overcomes ALK-TKI Resistance in
Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]